Pharmacokinetics and safety of ILX23-7553, a non-calcemic-vitamin D 3 analogue, in a phase I study of patients with advanced malignancies

Investigational New Drugs

Volumn 21, Issue 4, 2003, Pages 445-452

  Wieder, Robert ^a   Novick, Steven C ^b   Hollis, Bruce W ^c   Bryan, Margarette ^a   Chanel, Suzanne M ^b   Owusu, Kate ^a   Camastra, Danielle ^b   Saunders, Tracie ^a   Pliner, Lillian ^a   Harrison, Jonathan ^a   Bonate, Peter ^d   Williams, Tom ^d   Soignet, Steven ^b  

^a RUTGERS NEW JERSEY MEDICAL SCHOOL   (United States)

^b MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^c MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

^d Ilex Oncology Inc   (United States)

Author keywords

Advanced malignancies; Differentiation; Response; Vitamin D3

Indexed keywords

9,10 SECOCHOLESTA 5,7,10(19),16 TETRAEN 23 YNE 1,3,25 TRIOL; BUTYLATED HYDROXYANISOLE; BUTYLCRESOL; CALCITRIOL DERIVATIVE; CALCIUM; ILX 23 7553; MIGLYOL; MITOMYCIN C;

ABDOMINAL CRAMP; ADENOCARCINOMA; AREA UNDER THE CURVE; ARTICLE; BLADDER CARCINOMA; BREAST CARCINOMA; CANCER; CANCER CHEMOTHERAPY; CARCINOID; CLINICAL ARTICLE; CLINICAL TRIAL; COLORECTAL CARCINOMA; CONCENTRATION RESPONSE; CONSTIPATION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DRUG DOSE; DRUG EFFECT; DRUG FORMULATION; DRUG SAFETY; DYSPEPSIA; ESOPHAGUS CARCINOMA; FATIGUE; FEMALE; GASTROINTESTINAL SYMPTOM; HEADACHE; HUMAN; HYPERCALCEMIA; IN VITRO STUDY; KIDNEY CARCINOMA; LEIOMYOSARCOMA; LIPOSARCOMA; LIVER CELL CARCINOMA; LUNG NON SMALL CELL CANCER; LYMPHOMA; MALE; MAXIMUM TOLERATED DOSE; MELANOMA; METASTASIS; MUSCLE WEAKNESS; NAUSEA; OVARY CARCINOMA; PAIN; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; PROSTATE CARCINOMA; QUALITY OF LIFE; SQUAMOUS CELL CARCINOMA; TESTIS CARCINOMA; THYROID CARCINOMA; UTERINE CERVIX CARCINOMA; UTERUS MYOMA; VAGINA CARCINOMA;

ADULT; AGED; AGED, 80 AND OVER; AREA UNDER CURVE; CHOLECALCIFEROL; FEMALE; GASTROINTESTINAL DISEASES; HUMANS; MALE; MIDDLE AGED; NEOPLASMS;

EID: 9144250959     PISSN: 01676997     EISSN: None     Source Type: Journal    
DOI: 10.1023/A:1026203418976     Document Type: Article

References (42)

1. Norton L: Evolving concepts in the systemic drug therapy of breast cancer. Seminars in Oncology 24: S10-3-S10-10, 1997
2. Reichel H, Koeffler HP, Norman AW: The role of the vitamin D endocrine system in health and disease. N Eng J Med 320: 980-991, 1989
3. Carlberg C, Bendik I, Wyss A, Meier E, Sturzenbecker LJ, Grippo JF, Hunziker W: Two nuclear signalling pathways for vitamin D. Nature 361: 657-660, 1993
4. 3 leads to induced differentiation of the myelomonocytic cell line U937. Genes Dev 10: 142-153, 1996
5. 3 in HL60 cells. Cancer Res 56: 264-267, 1996
6. 3-treated HL60 cells. Cancer Res 57: 2851-2855, 1997
7. 3-resistant variant. Endocrinology 138: 4690-4698, 1997
8. DeLuca HF: The vitamin D story: a collaborative effort of basic science and clinical medicine. FASEB J 2: 224, 1988
9. 3 and retinoic acid analogues induce differentiation in breast cancer cells with function-and cell-specific additive effects. Breast Cancer Res Treat 67: 157-168, 2001
10. Welsh JE, Simboli-Campbell M, Narvaez CJ, Tenniswood M: Role of apoptosis in the growth inhibitory effect of vitamin D in MCF-7 cells. Adv Exp Med Biol 375: 45-52, 1995
11. 3 and all-trans retinoic acid sensitize breast cancer cells to chemotherapy-induced cell death. Cancer Res 60: 2040-2048, 2000
12. Light BJ, Yu W-D, McElwain MC, Russell DM, Trump DL, Johnson CS: Potentiation of cisplatin tumor activity using a vitamin D analogue in a murine squamous cell carcinoma model system. Cancer Res 57: 3759-3764, 1997
13. Smith DC, Johnson CS, Freeman CC, Muindi J, Wilson JW, Trump DL: A phase I trial of calcitriol (1,25-dihydroxycholecalciferol) in patients with advanced malignancy. Clin Cancer Res 5: 1339-1345, 1999
14. Zhou JY, Norman AW, Lubbert M, Collins ED, Uskokovic MR, Koeffler HP: Novel vitamin D analogs that modulate leukemic cell growth and differentiation with little effect on either intestinal calcium absorption or bone calcium mobilization. Blood 74: 82-93, 1989
15. 3 prolongs survival time of leukemic mice. Proc Natl Acad Sci USA 87: 3929-3932, 1990
16. 125I-labeled tracer. Clin Chem 39: 529-33, 1993
17. 3-induced growth restriction of cultured epithelial cells derived from a murine hepatic tumor. Biochem Pharm 38: 449-453, 1989
18. 3 receptor mRNA in the proliferation of hepatocellular carcinoma. Hepato-Gastroenterology 47: 468-472, 2000
19. 3 on metastasis of rat ascites hepatoma K-231. Br J Cancer 50: 123-125, 1984
20. 3 on the growth of the renal carcinoma cell line. Kidney Internat 29: 834-840, 1986
21. 3 increases the sensitivity of human renal carcinoma cells to tumor necrosis factor α but not to interferon α or lymphokine-activated killer cells. J Endocrinol 149: 327-333, 1996
22. Mezzetti G, Bagnara GP, Monti MG, Pernecco Casolo L, Bonsi L, Brunelli MA: Phorbol esters, but not the hormonal form of vitamin D, induce changes in protein kinase C during differentiation of human histiocytic lymphoma cell line (U-937). Life Sci 40: 2111-2117, 1987
23. Dodd RC, Cohen MS, Newman SL, Gray TK: Vitamin D metabolites change the phenotype of monoblastic U937 cells. Proc Natl Acad Sci USA 80: 7538-7541, 1983
24. Mathiasen IS, Colston KW, Binderup L: EB 1089, a novel vitamin D analogue, has strong antiproliferative and differentiation inducing effects on cancer cells. J Steroid Biochem Mol Biol 46: 365-371, 1993
25. 3 on lymphoma cell lines and expression of vitamin D receptor in lymphoma. Br J Cancer 68: 668-672, 1993
26. Raina V, Cunningham D, Gilchrist N, Soukop M: Alfacalcidiol is a nontoxic, effective treatment of follicular small-cleaved cell lymphoma. Br J Cancer 63: 463-465, 1991
27. 3 on human prostate cancer cell line LNCaP involves reduction of cyclin-dependent kinase 2 activity and persistent G1 accumulation. Endocrinology 139: 1197-1207, 1998
28. 2 as therapeutic agents for prostate cancer. Clin Cancer Res 6: 901-908, 2000
29. Hedlund TE, Moffatt KA, Uskokovic MR, Miller GJ: Three synthetic vitamin D analogues induce prostate-specific acid phosphatase and prostate-specific antigen while inhibiting the growth of human prostate cancer cells in a vitamin D receptor-dependent fashion. Clin Cancer Res 3: 1331-1338, 1997
30. 3. Endocrinology 136: 20-26, 1995
31. 3 inhibits prostate cancer cell growth by androgen-dependent and androgen-independent mechanisms. Endocrinology 141: 2548-2556, 2000
32. Krill D, Stoner J, Konety BR, Becich MJ, Getzenberg RH: Differential effects of vitamin D on normal human prostate epithelial and stromal cells in primary culture. Urology 54: 171-177, 1999
33. 3 on primary cultures of human prostatic cells. Cancer Res 54: 805-810, 1994
34. 3 decreases human prostate cancer cell adhesion and migration. Mol Cell Endocrinol 164: 133-143, 2000
35. 3 and 9-cis retinoic acid in LNCaP human prostate cancer cells. Endocrinology 140: 1205-1212, 1999
36. 3 receptors and actions in human prostate cancer cell lines. Endocrinology 132: 1952-1960, 1993
37. Blutt SE, McDonnell TJ, Polek TC, Weigel NL: Calcitriol-induced apoptosis in LNCaP cells is blocked by overexpression of Bcl-2. Endocrinology 141: 10-17, 2000
38. Getzenberg RH, Light BW, Lapco PE, Konety BR, Nangia AK, Acierno JS, Dhir R, Shurin Z, Day RS, Trump DL, Johnson CS: Vitamin D inhibition of prostate adenocarcinoma growth and metastasis in the Dunning rat prostate model system. Urology 50: 999-1006, 1997
39. Lokeshwar BL, Schwartz GG, Selzer MG, Burnstein KL, Zhuang S-H., Block NL, Binderup L: Inhibition of prostate cancer metastasis in vivo: a comparison of 1,25-dihydroxyvitamin D (calcitriol) and EB1089. Cancer Epidemiol Biomarkers Prevent 8: 241-248, 1999
40. 3 and prostate cancer cell proliferation in vivo. Urology 46: 365-369, 1995
41. 3 suppresses proliferation and immunoglobulin production by normal human peripheral blood mononuclear cells. J Clin Invest 74: 657-661, 1984
42. 3 (calcitriol). J Clin Invest 74: 1451-1455, 1984